Hot on heels of a positive PhIII, Ablynx files $150M IPO; Shire sues Allergan over dry eye drug rivalry

→ After watching its European share price surge {$ABLX BB} yesterday on positive Phase III data, Ablynx feels it’s perfect timing for an IPO on Nasdaq. The Belgian biotech is looking to raise around $150 million at a time a growing number of European biotechs have been finding a warm welcome on the exchange. The group is pushing a new drug for acquired thrombotic thrombocytopenic purpura, or aTTP.

→ An increasingly litigious Shire has now sued Allergan, claiming the rival violated antitrust laws in blocking patients from receiving its dry eye disease drug.

→ Intra-Cellular Therapies $ITCI has raised $150 million from the sale of stock.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->